Novus Biologicals and AmideBio sign distribution agreement

Novus Biologicals, LLC executed an exclusive distribution agreement  with Boulder-based startup, AmideBio, LLC to distribute their line of peptides to bioscience researchers worldwide. 

AmideBio develops and manufactures peptides based on IP licensed from the University of Colorado.  The inventor of this line of peptides is Dr. Michael Stowell, CU/MCDB, who is also the Chief Technology Officer for AmideBio.  Dr. Stowell's new manufacturing technique has the potential both to reduce costs and to make it feasible to manufacture drugs that were previously difficult to produce with conventional methods. 

“AmideBio’s manufacturing technology is ideally suited for the production of difficult to produce peptides critical for biomedical research. We are happy that Novus Biologicals recognizes the unique capabilities of AmideBio by partnering with us to manufacture and distribute peptides, many of which were previously unavailable to the research community” said Dr. Stowell, AmideBio CTO.

Initial commercial efforts will focus on Novus’ dissemination of the Amyloid family of peptides for the study of Alzheimer's disease.  The AmideBio peptides will be available globally from Novus Worldwide headquarters in Littleton, CO and from Novus Europe based in Cambridge, UK.

Novus and AmideBio are both members of the Colorado BioScience Association, an organization that facilitates the growth of the industry in Colorado through advocacy, representation and service.  


About Novus Biologicals, LLC (
Novus Biologicals is a biotechnology company whose mission is to accelerate scientific discovery by developing and marketing unique products in the forefront of science. Novus Biologicals manufactures and distributes antibodies, proteins, peptides, lysates, antibody labeling kits, isotype controls, RNAi and other research reagents to the bioscience community.  By making these products widely available to institutional and commercial researchers, Novus Biologicals plays an important role in furthering biological research.

About AmideBio, LLC (
AmideBio based in Boulder, CO is a biotechnology company focused on providing recombinant peptide research and clinical products for a diverse array of disease research and disease targets. AmideBio maintains a proprietary platform vector technology that addresses the challenges of historically difficult to manufacture peptides by providing products that are reliable (BioPureâ„¢), economical and incorporate environmentally sustainable practices.

Novus Contact:
Zach Kiebler
VP - OEM and Supplier Relationship Management

AmideBio Contact:
Misha Plam
Co-Founder, President & CEO

Release Date: 
Thursday, July 1, 2010 - 06:00